Abzena, a provider of integrated discovery to GMP solutions for biologics and bioconjugates, and evitria AG, a transient antibody expression service provider, have formed a partnership to enhance lead candidate selection for large molecules. This collaboration will leverage evitria’s reputation in rapid transient production of antibodies alongside Abzena’s lead candidate design and developability expertise underpinned by a comprehensive range of bioassay and analytical capabilities.   The part...